Persistence of Candida dubliniensis and lung function in patients with cystic fibrosis

被引：15

作者：

AbdulWahab A. ^{[1
,2
]}

Salah H. ^{[3
,4
]}

Chandra P. ^{[5
]}

Taj-Aldeen S.J. ^{[2
,3
]}

机构：

[1] Departments of Pediatrics, Hamad Medical Corporation, Doha

[2] Weill Cornell Medicine, Doha

[3] Microbiology Division, Laboratory of Medicine and Pathology, Hamad Medical Corporation, Doha

[4] CBS Fungal Biodiversity Center, Utrecht

[5] Department of Medical Research, Hamad Medical Corporation, Doha

来源：

BMC Research Notes | / 10卷 / 1期

关键词：

BMI; Candida dubliniensis; Cystic fibrosis; FEV1%; Lung function;

D O I：

10.1186/s13104-017-2656-z

中图分类号：

学科分类号：

摘要：

Objectives: Candida dubliniensis is an emerging yeast and demonstrated a high adherence property to cystic fibrosis respiratory tract. Therefore, it is important to determine the persistence of C. dubliniensis and to assess the possible relationship to the body mass index (BMI) and forced expiratory volume in 1st second (FEV1). Results: Candida isolates were identified by MALDI-TOF MS to species level from 40/52 (76.9%) cystic fibrosis patients. C. dubliniensis was the most common organism isolated from 50/77 (65%) lower respiratory specimens of 29 patients. Patients with persistent C. dubliniensis isolates have higher mean BMI in comparison to intermittent C. dubliniensis group. However, this difference did not reach statistical significance (P = 0.539). In contrast, patients with persistent C. dubliniensis isolates have significantly lower FEV1% mean in comparison to intermittent C. dubliniensis group particularly at initial two visits (P < 0.05); however, at subsequent visit the difference observed was not statistically significant (P = 0.456). The persistence of C. dubliniensis is more frequent in adults having more advanced disease, co-infections with chronic P. aeruginosa, cystic fibrosis related diabetes, long-term nebulized tobramycin and oral Zithromax therapy than patients with intermittent C. dubliniensis. Patients with persistent C. dubliniensis have lower FEV1 percentage and higher BMI than the intermittent C. dubliniensis. © 2017 The Author(s).

引用

共 25 条

[1]

Lipuma J.J., The changing microbial epidemiology in cystic fibrosis, ClinMicrobiol Rev., 23, pp. 299-323, (2010)

[2]

Surette M.G., The cystic fibrosis lung microbiome, Ann Am Thorac Soc, 11, pp. S61-S65, (2014)

[3]

Chotirmall S.H., McElvaney N.G., Fungi in the cystic fibrosis lung: Bystanders or pathogens?, Int J Biochem Cell Biol, 52, pp. 161-173, (2014)

[4]

Hong G., Miller H.B., Allgood S., Lee R., Lechtzin N., Zhang S.X., Use of selective fungal culture media increases rates of detection of fungi in the respiratory tract of cystic fibrosis patients, J Clin Microbiol, 55, pp. 1122-1130, (2017)

[5]

Nagano Y., Millar B.C., Johnson E., Et al., Fungal infections in patients with cystic fibrosis, Rev Med Microbiol, 18, pp. 11-16, (2007)

[6]

Muthig M., Hebestreit A., Ziegler U., Seidler M., Muller F.M., Persistence of Candida species in the respiratory tract of cystic fibrosis patients, Med Mycol, 48, pp. 56-63, (2010)

[7]

Bakare N., Rickerts V., Bargon J., Just-Nubling G., Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis, Mycoses, 46, pp. 19-23, (2003)

[8]

Gutierrez J., Morales P., Gonzalez M.A., Quindos G., Candida dubliniensis, a new fungal pathogen, J Basic Microbiol, 42, pp. 207-227, (2002)

[9]

Meis J.F.G.M., Ruhnke M., De Pauw B.E., Odds F.C., Siegert W., Verweij P.E., Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation, Emerg Infect Dis, 5, pp. 150-153, (2000)

[10]

Peltroche-Llacsahuanga H., Dohmen H., Haase G., Recovery of Candida dubliniensis from sputum of cystic fibrosis patients, Mycoses, 45, pp. 15-18, (2002)

← 1 2 3 →